AKBA logo

Akebia Therapeutics, Inc.

AKBA
Healthcare|Biotechnology|US
$0.40
-0.02 (-5.69%)
Cash / Share
$0.58
Next Earnings Report
Feb 25, 2027
EPS est. -$0.04 · Revenue est. $48.2M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (4)

Dec 2026
Est. completion
P1Healthy Volunteers
SAD and MAD Study of AKB-9090 in Healthy Adult Participants
NCT07429006n=44
Jun 2027
Est. completion
P2Focal Segmental Glomerulosclerosis
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638n=60
Feb 2028
Est. completion
P2IgA Nephropathy
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
NCT06419205n=30
May 2031
Est. completion
P2P3Nonintubated Acute Respiratory Distress Syndrome (ARDS)
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
NCT07086755n=1,100

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P3
Vafseo Outcomes In-Center Experience
NCT06520826

Recent Press Releases

Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Nov 5, 2026 · GlobeNewsWire
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
Nov 5, 2026 · GlobeNewsWire
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
Oct 29, 2026 · GlobeNewsWire
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
Oct 26, 2026 · GlobeNewsWire
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Oct 7, 2026 · GlobeNewsWire
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026
Oct 6, 2026 · GlobeNewsWire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2026 · GlobeNewsWire
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Sep 14, 2026 · GlobeNewsWire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2026 · GlobeNewsWire
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
Sep 1, 2026 · GlobeNewsWire

SEC Filings (49)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 23, 20268-KMaterial eventDocumentIndex
Oct 14, 20268-KMaterial eventDocumentIndex
Aug 5, 2026S-8Employee stock planDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Jun 30, 20268-KMaterial eventDocumentIndex
Jun 22, 20268-KMaterial eventDocumentIndex
May 12, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 7, 202610-QQuarterly reportDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
Apr 29, 2026ARSAnnual report to holdersDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 15, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 1, 20268-KMaterial eventDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 9, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 30, 20268-KMaterial eventDocumentIndex
Jan 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 1, 20258-KMaterial eventDocumentIndex
Nov 17, 20258-KMaterial eventDocumentIndex
Nov 10, 202510-QQuarterly reportDocumentIndex
Nov 10, 20258-KMaterial eventDocumentIndex
Oct 28, 20258-KMaterial eventDocumentIndex
Aug 7, 2025S-8Employee stock planDocumentIndex
Aug 7, 202510-QQuarterly reportDocumentIndex
Aug 7, 20258-KMaterial eventDocumentIndex
Jun 13, 20258-KMaterial eventDocumentIndex
May 8, 202510-QQuarterly reportDocumentIndex
May 8, 20258-KMaterial eventDocumentIndex
Apr 30, 2025SC 13GPassive 5%+ stakeDocumentIndex
Apr 29, 2025ARSAnnual report to holdersDocumentIndex
Apr 29, 2025DEFA14AProxy / shareholder voteDocumentIndex
Apr 29, 2025DEF 14AProxy / shareholder voteDocumentIndex
Apr 17, 2025SC 13G/APassive 5%+ stakeDocumentIndex